Galectin-3 levels in patients with hypertrophic cardiomyopathy and its relationship with left ventricular mass index and function.

Creative Commons License

Tuluce S. Y., Tuluce K., Cil Z., EMREN S. V., Akyildiz Z. I., Ergene O.

Anatolian journal of cardiology, cilt.16, sa.5, ss.344-8, 2016 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 16 Sayı: 5
  • Basım Tarihi: 2016
  • Doi Numarası: 10.5152/anatoljcardiol.2015.6191
  • Dergi Adı: Anatolian journal of cardiology
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.344-8
  • Anahtar Kelimeler: Galectin-3, hypertrophic cardiomyopathy, left ventricular mass index, strain imaging, MYOCARDIAL FIBROSIS, HEART-FAILURE, MAGNETIC-RESONANCE, DIASTOLIC FUNCTION, RECOMMENDATIONS, ASSOCIATION, BIOMARKERS
  • Dokuz Eylül Üniversitesi Adresli: Evet

Özet

Objective: Cardiac fibrosis is an important contributor to adverse left ventricular (LV) remodeling and arrhythmias in patients with hypertrophic cardiomyopathy (HCM). Galectin-3 (Gal-3) is a novel marker of cardiac fibrosis and inflammation. In this study, we investigated Gal-3 levels in patients with HCM and controls and assessed the relationship between Gal-3 level and echocardiographic indices using strain echocardiography in patients with HCM.